Considering the poor prognosis of B-ALL patients with MLL-r, the patient received blinatumomab as maintenance therapy from 3 months post-transplantation as an infusion from 9 to 18 μg/day for 7 days. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.